The young Swiss company Kenta Biotech will work with the Laupheim-based contract manufacturer Rentschler to develop a fully human monoclonal antibody against methicillin-resistant Staphylococcus aureus (MRSA).
Using Kenta's proprietary hybridoma cell line, Rentschler will develop a manufacturing process for Kenta's KBSA301 antibody using single-use bioreactor technology for the first time ever. Financial details of the agreement have not been disclosed. KBSA301 is a fully human IgG (immunoglobulin G) antibody designed to treat infections caused by MRSA, bacteria that can become resistant to certain antibiotics, including methicillin, oxacillin, penicillin and amoxicillin. KBSA301 has shown in several preclinical animal models that the antibody is very effective in treating severe S. aureus infections. This was announced in a press release jointly published by Rentschler and Kenta Biotech.
MRSA occurs most frequently in patients with weakened immune systems who are in long-term care facilities or in hospital. Such patients are at risk because the use of a number of invasive medical devices and the frequent use of broad-spectrum antibiotics promotes the colonisation of hospital pathogens.Hospital-acquired MRSA can cause serious and potentially life-threatening infections, such as bloodstream infections, surgical site infections and pneumonia. These infections are difficult to treat and lead to prolonged hospitalisation, high costs and increased morbidity and mortality. The mortality rate of patients suffering from MRSA blood stream infections varies from 24% to 64% as reported by Decision Resources (MRSA, Dec. 2009).